Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

March 21 - 22, 2014

San Francisco, California

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum 10.0 of AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for gastroenterologists, pediatric gastroenterologists, IBD sub-specialists, internists, physician assistants, nurse practitioners, gastroenterology nurses, gastroenterology mid-level providers, gastrointestinal surgeons, clinical researchers, and other healthcare professionals with an interest in the treatment of pediatric and adult patients with IBD.

Objectives

Upon completion of this educational activity, participants should be able to:

  • Evaluate current emerging therapies for pediatric patients with IBD to enhance treatment outcomes
  • Assess risk stratification and optimal therapeutic strategies in treating pediatric IBD
  • Explain the role of immunomodulators and biologics in pediatric IBD as it pertains to the use of mucosal and transmural healing
  • Review the role of bone monitoring and sexuality as it relates to transition of care in the developing adolescent IBD patient population
  • Identify out of the box strategies to manage pediatric IBD patients with unique therapeutic needs by using fecal microbiota transplantation (FMT), cannabis and worms
  • Summarize the nutritional aspects of managing pediatric patients with IBD to optimize growth and development
  • Review treatment precautions for pregnant and breast feeding women to prevent adverse effects in offspring
  • Explain the role of health maintenance and how it impacts quality measures for patients with IBD
  • Translate the predicative value of IBD-associated genetic links into future actionable targets that can be incorporated into clinical practice
  • Implement a personalized therapeutic drug monitoring approach to optimize therapeutic dosing for patients with IBD  
  • Discuss the use of biologic and immunobiologic therapies in various surgical settings
  • Describe the benefits of using mucosal healing as a primary outcome in ulcerative colitis
  • Review the use of colectomy as a treatment for dysplasia and polyps in ulcerative colitis

The following ACGME/ABMS Core Competencies will be addressed in this activity:
Medical Knowledge

Practice-Based Learning and Improvement